Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Use of hR3 MaB and radiotherapy in treatment of patients with highly malignant astrocytic tumors, phase III

Next Previous
X
Search
Trial Profile

Use of hR3 MaB and radiotherapy in treatment of patients with highly malignant astrocytic tumors, phase III

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors YM BioSciences

    • Most Recent Events

    • 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry.
    • 02 Jun 2012 Results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Nov 2008 A total of 65 patients (all with glioblastoma) have been enrolled as of the 3rd Nov 2008, according to a YM Biosciences media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top